PPAR-GammaER stressAim This study sought to evaluate the effects of LDT409, a pan-PPAR partial agonist obtained from the main industrial waste from cashew nut processing, on hepatic remodeling, highlighting energy metabolism and endoplasmic reticulum (ER) stress in high-fructose-fed mice. Methods ...
pan-PPAR agonistsreceptorsresveratrolThe peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor superfamily and consist of three receptor isoforms,PPARα,PPARy,and PPARδ,which play important roles in carbohydrate and lipid metabolism.PPARα agonists such as fenofibrate,...
In M1-polarized THP-1 cells, the reduction in the mRNA expression of inflammatory cytokines was more significant in pan-PPAR-iMSC-EVs than that in iMSC-EVs. In the mouse model of cisplatin-induced AKI, pan-PPAR-iMSC-EVs markedly enhanced renoprotective effects compared to iMSC-EVs. ...
摘要 目的探讨PPAR-α激动剂非诺贝特对氨基核苷嘌呤霉素(PAN)诱导肾小球足细胞损伤的作用及其机制。方法将18只8周龄SD♀大鼠随机分为3组(n=6)。PAN模型组和非诺贝特组1次尾静脉注射PAN 65 g·g-...展开更多 Aim To investigate the function of fenofi-brate on PAN ( puromycin aminonucleoside )-induced ...
Although the antifibrotic effect of pan PPAR was similar to that of PPARγ agonist alone, a significant downregulation of several markers of inflammation was associated with IVA337. Despite its anti-inflammatory and antifibrotic properties, IVA337 did not interfere with wound closure. In vitro ...
尽管在许多肾脏疾病中,PPAR-α都表现出保护作用,但是其在氨基核苷嘌呤霉素(PAN)诱导的大鼠肾小球足细胞损伤中的作用报道较少。因此,我们拟通过建立PAN大鼠肾小球足细胞损伤模型,以尿蛋白水平的上升和足细胞损伤标志物desmin的表达上调作为成模型标准,通过PPAR-α特异性激动剂非诺贝特予以治疗,探索PPAR-α激动剂非诺贝特...
PPAR-α激动剂对PAN诱导肾小球足细胞损伤的保护作用 许俊铭;潘方瑜;刘源;岳晓阳;邹军 【期刊名称】《中国药理学通报》 【年(卷),期】2014(000)010 【摘要】Aim To investigate the function of fenofi-brate on PAN ( puromycin aminonucleoside )-induced podocyte injury. Methods SD female rats of 18-week...
Due to the undesirable side-effects, many PPAR agonists including PPARα/γ and PPARβ/γ dual agonists are stopped by US FDA in the clinical trials. An alternative strategy is to design novel pan-agonist that can simultaneously activate PPARα, PPARβ and PPARγ...
Due to the undesirable side-effects, many PPAR agonists including PPARα/γ and PPARβ/γ dual agonists are stopped by US FDA in the clinical trials. An alternative strategy is to design novel pan-agonist that can simultaneously activate PPARα, PPARβ and PPARγ. Under such an idea, in ...
内容提示: Scaffold-Based Pan-Agonist Design for the PPARa, PPARband PPARc ReceptorsLi-Song Zhang 1. , Shu-Qing Wang 1. , Wei-Ren Xu 2 , Run-Ling Wang 1 *, Jing-Fang Wang 3,4 *1Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (...